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A B S T R A C T
Using liquid chromatography – mass spectrometry in combination with derivatisation chemistry we proﬁled the
oxysterol and cholestenoic acid content of cerebrospinal ﬂuid from patients with Alzheimer's disease (n=21),
vascular dementia (n=11), other neurodegenerative diseases (n=15, Lewy bodies dementia, n= 3,
Frontotemporal dementia, n= 11) and controls (n=15). Thirty diﬀerent sterols were quantiﬁed and the bile
acid precursor 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid found to be reduced in abundance in cere-
brospinal ﬂuid of Alzheimer's disease patient-group. This was the only sterol found to be changed amongst the
diﬀerent groups.
1. Introduction
Cholesterol has been linked to the aetiology of Alzheimer's disease
(AD) for decades with the ε4 allele of apolipoprotein E gene (APOE)
being the most robust genetic risk factor for sporadic AD [1,2]. More
recently cholesterol metabolism-related genes including ABCA7 (ATP
binding cassette subfamily A member 7), ABCG1 (ATP binding cassette
subfamily G member 1), CLU (apolipoprotein J) and SORL1 (LDLR re-
lative with 11 ligand-binding repeats) have been classiﬁed among
susceptibility loci by large genome-wide association studies (GWAS)
[3,4]. Furthermore, in 2018 Picard et al. reported that polymorphism
rs2269657 of the SREBF2 gene, which codes for the protein sterol
regulatory element-binding protein-2 (SREBP-2), the master transcrip-
tion factor regulating cholesterol biosynthesis, showed signiﬁcant dual
association with late-onset AD pathological biomarkers and gene ex-
pression levels [5]. Expression levels of the rs2269657 allele of SERBF2
in frontal cortex from late-onset AD brain inversely correlated with
plaque density and with age at death [5].
Cholesterol is abundant in brain (2% wet weight) with about 25% of
the total body cholesterol being found in brain [6]. Cholesterol cannot
cross the blood brain barrier (BBB), hence after parturition essentially
all cholesterol in brain is synthesised in situ from acetyl CoA, and all
cholesterol export is via metabolism [6]. The ﬁrst step of cholesterol
metabolism is formation of an oxysterol, an oxidised form of choles-
terol, and subsequent metabolism leads to steroid hormones and bile
acids [7], i.e. in the central nervous system (CNS) to neurosteroids and
C27 bile acids [8,9]. In brain the dominant oxysterol is 24S-hydro-
xycholesterol [10], formed in neurons by oxidation of cholesterol by
CYP46A1 (cytochrome P450 family 46 subfamily A member 1) [11],
this can be metabolised further in CNS [12] or exported as the intact
molecule over the BBB [13]. Björkhem and colleagues have suggested
the balance between 24S-hydroxycholesterol and its positional isomer
(25 R)26-hydroxycholesterol (common name 27-hydroxycholesterol) in
brain may aﬀect the production of beta-amyloid in brain [14]. (25R)26-
Hydroxycholesterol may be formed via CYP27A1 (cytochrome P450
family 27 subfamily A member 1) mediated oxidation of cholesterol in
brain or imported into brain from extracerebral sources [14–16]. (25R)
26-Hydroxycholesterol is elevated in AD brain [17] and Björkhem et al.
have suggested (25R)26-hydroxycholesterol may provide a missing link
between hypercholesterolemia and AD [14].
While it is diﬃcult to investigate brain from living subjects, cere-
brospinal ﬂuid (CSF), the ﬂuid which bathes the brain, is available.
Papassotiropoulos et al. and Schönknecht et al. found elevated CSF
concentrations of 24S-hydroxycholesterol in AD patients, which they
explained by increased cholesterol turnover during neurodegeneration
[18,19]. Surprisingly, this elevation is not evident in AD plasma [14].
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CYP46A1 is normally expressed in neurons [11], but in AD is also ex-
pressed in glia cells [20]. 24S-Hydroxycholesterol reduces expression of
enzymes of the cholesterol biosynthesis pathway in mouse neurons and
glia, presumably by inhibiting the processing of SREBP-2 to its active
form as a transcription factor, but up-regulates expression of APOE
[21,22]. ApoE is a target gene of liver X receptors (LXRα and β, NR1H3
and NR1H2), both of which are expressed in mouse brain [23], and
known to be activated by oxysterols, including 24S-hydroxycholesterol
[24]. (25 R)26-Hydroxycholesterol has also been found to be elevated
in CSF from AD patients [25,26].
The end products of cholesterol metabolism include bile acids and
steroid hormones. Intermediates in the bile acid biosynthesis pathways
have been observed in human and rodent CSF [8,9,12,27,28] and brain
[29,30], while bile acids have been found in rodent [29,31,32] and
human brain [33]. Pan et al. found levels of taurocholic acid were re-
duced in AD brain [33]. When plasma was analysed they found cholic
acid to be reduced in AD patients [33]. Others have found lithocholic
acid to be increased in plasma from AD patients [34], while in an un-
targeted metabolomics study the glycine conjugates of cholic acid,
deoxycholic acid and chenodeoxycholic acid have been found to be
elevated in AD plasma [35].
In an eﬀort to understand further the relationship between choles-
terol metabolism and AD we have proﬁled the oxysterol content of CSF
from AD patients, those with vascular dementia (VD) and other neu-
rodegenerative disease (OND), and normal controls with no evidence of
“normal pressure hydrocephalus” (NPH). We have extended the proﬁle
to include cholesterol and its immediate precursors and intermediates
in the acidic-, neutral-, 24S-hydroxylase- and 25-hydroxylase-pathways
of bile acid biosynthesis. Of the 30 sterols routinely identiﬁed in CSF,
between the diﬀerent patient/control groups, only one was changed in
abundance in CSF, whether normalised to the cholesterol content (ng/
µg-cholesterol) or measured in ng/mL, this was the bile acid precursor
7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid which was reduced in
concentration in CSF from the AD group.
2. Methods
2.1. Biomaterial
CSF samples were obtained from patients evaluated at the Memory
Clinic, Methodist Hospital, Houston, because of complaints of memory
loss. They were all found to have enlarged ventricles and were con-
sidered “probable NPH”. A spinal tap was performed to conﬁrm or not
the diagnosis of NPH. After the spinal tap with removal of CSF (material
analysed in the current study) the following diagnostic categories were
concluded: (i) No evidence of NPH (these are considered “normal”
controls, n= 15); cases of NPH plus (ii) AD, n=21, (iii) OND, n=15,
including Lewy bodies dementia, LBD, n=3; Frontotemporal
Dementia, FTD, n=11) and Vascular Dementia (VD, n=11, See
Supplemental Table S1 for diagnostic information). All the CSF samples
were obtained with a similar technique under ﬂuoroscopy by a hospital
neuroradiologist. Participants in the study gave written, informed
consent to participate in the study, which was conducted according to
the Declaration of Helsinki and its subsequent amendments.
2.2. Methods
Sterols including oxysterols and bile acid precursors were analysed
by liquid chromatography (LC) – mass spectrometry (MS) incorporating
charge-tagging methodology, termed “Enzyme-Assisted Derivatization
for Sterol Analysis” (EADSA) [9,36,37]. The method is fully described
in Abdel-Khalik et al. [9]. In brief, sterols were extracted into ethanol
from CSF, oxidised with cholesterol oxidase and derivatized with
deuterated Girard P reagent ([2H5]GP). A separate aliquot of extract
was similarly derivatized with [2H0]GP in the absence of enzyme
(Supplemental Fig. S1). The derivatives were combined and analysed
by LC-MS, exploiting high mass-resolution (120,000, full-width at half-
maximum height deﬁnition) and multistage fragmentation (MSn).
Quantiﬁcation was achieved, where possible, by the addition of isotope-
labelled standards. In the absence of an exact isotope-labelled standard
quantiﬁcation was made against isotope-labelled structural-analogues
(See Supplemental Tables S2–S4) [9,37]. Crick et al. and Karu et al.
have previously demonstrated the eﬃciency of the extraction, deriva-
tisation and puriﬁcation methods and Crick et al. validated the method
for multiple sterols and C27 bile acids [37,38]. Here, despite the absence
of an authentic isotope-labelled standard for 7α,25-dihydroxy-3-ox-
ocholest-4-en-26-oic acid we have conﬁrmed the validity of using [2H7]
24(R/S)-hydroxycholesterol as its internal standard by the standards
addition method, adding consecutively increasing amounts of acid
(0.2 ng/mL – 0.8 ng/mL) to a pooled CSF sample containing a set
concentration of [2H7]24(R/S)-hydroxycholesterol (8 ng/mL).
2.3. Statistics
An ANOVA was run against each sterol. Univariate t-tests were
performed against the control group. P < 0.05 (*) is considered sta-
tistically signiﬁcant. Concentrations in the text are given in units of ng/
mL or ng/µg-cholesterol as mean± standard deviation (SD).
3. Results
In the current study we measured the concentrations of unesteriﬁed
“free” sterols, oxysterols and bile acid precursors in the absence of sa-
poniﬁcation or solvolysis. This contrasts to most other studies of sterols
and oxysterols by other groups where a solvolysis step is included to
hydrolyse fatty acid esters [18,19,25]. Data for the control sample set
has been reported previously in [9]. In the absence of authentic isotope-
labelled standards for cholestenoic acids, [2H7]24(R/S)-hydro-
xycholesterol was used as the internal standard. This selection has
previously been validated by Crick et at for some C27 acids [37] and
here speciﬁcally for 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid
using the standard additions method where a plot of measured con-
centration against theoretical concentration gave a straight line with
R2> 0.994.
3.1. Oxysterols in CSF
The concentrations of monohydroxycholesterols, dihydrox-
ycholesterols and dihydroxycholest-4-en-3-ones in CSF are low, ranging
from about the limit of quantiﬁcation of the method, 0.01 ng/mL, for
the dihydroxysterols to about 0.1 ng/mL for (25 R)26-hydro-
xycholesterol and 7β-hydroxycholesterol (Supplemental Tables S2 and
S3). There was no statistically signiﬁcant diﬀerence in concentration
measured, as either ng/mL or ng/µg-cholesterol, in any of the oxy-
sterols investigated between the diﬀerent sample groups ( Figs. 1 and 2,
Supplemental Fig. S2).
3.2. Bile acid precursors in CSF
As in other studies [8,9,12,27,28], we measured intermediates of
the acidic pathway of bile acid biosynthesis in CSF (Supplemental Fig.
S3). These include 3β-hydroxycholest-5-en-(25 R)26-oic acid, its
CYP7B1 (cytochrome P450 family 7 subfamily B member 1) metabolite,
3β,7α-dihydroxycholest-5-en-(25 R)26-oic acid and the 3-oxo metabo-
lite, 7α-hydroxy-3-oxocholest-4-en-(25 R)26-oic acid, formed by oxi-
dation at C-3 and Δ5-Δ4 isomerisation by HSD3B7 (3beta-hydro-
xysteroid dehydrogenase type 7). The latter compound is present at
high levels (~28 ng/mL, ~40 ng/µg-cholesterol) in CSF (Fig. 2, see also
Supplemental Fig. S4 and Tables S2 & S3). 7α-Hydroxy-3-oxocholest-4-
en-(25 R)26-oic acid can be metabolised in the peroxisome to the Co-A
thioesters of 7α,24R-dihydroxy-3-oxocholest-4-en-(25 R)26-oic acid,
then 7α-hydroxy-3,24-bisoxocholest-4-en-(25 R)26-oic acid and
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Fig. 1. Dot-plots displaying the concentrations of diﬀerent oxysterols in CSF. Each dot indicates an individual patient sample. Concentrations are in ng/µg-cho-
lesterol. The black bars indicate the mean value for each group. There were no statistical diﬀerences between the disease and control groups. (A) 24S-HC, 24S-
hydroxycholesterol; (B) 25-HC, 25-hydroxycholesterol; (C) (25 R)26-HC, (25 R)26-hydroxycholesterol; (D) 25D3, 25-hydroxyvitamin D3; (E) 7α-HC, 7α-hydro-
xycholesterol; (F) 7β-HC, 7β-hydroxycholesterol; (G) 7O-C, 7-oxocholesterol. Abbreviations: - AD, Alzheimer's disease; VD, vascular dementia; OND, other neuro-
degenerative diseases (i.e. Lewy bodies dementia, Frontotemporal dementia).
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Fig. 2. Dot-plots displaying the concentrations of diﬀerent dihydroxysterols and cholestenoic acids in CSF. Each dot indicates an individual patient sample.
Concentrations are in ng/µg-cholesterol. The black bar indicates the mean value. (A) 7α,(25 R)26-diHCO, 7α,(25 R)26-dihydroxycholest-4-en-3-one; (B) 7α,25-
diHCO, 7α,25-dihydroxycholest-4-en-3-one; (C) 3β-HCA, 3β-hydroxycholest-5-en-(25 R)26-oic acid; (D) 3O-CA, 3-oxocholest-4-en-(25 R)26-oic acid; (E) 3β,7α-
diHCA, 3β,7α-dihydroxycholest-5-en-(25 R)26-oic acid; (F) 7αH,3O-CA, 7α-hydroxy-3-oxocholest-4-en-(25 R)26-oic acid; (G) 3β,7β-diHCA, 3β,7β-dihydroxycholest-
5-en-(25 R)26-oic acid.
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ultimately 7α-hydroxy-3-oxochol-4-en-24-oic acid [30,39]. In our assay
we observe the hydrolysed thioesters, but, in the absence of authentic
standards of the diﬀerent diasteriomers, could not determine the ste-
reochemistry at C-25. 7α,24-Dihydroxy-3-oxocholest-4-en-26-oic acid
could also be derived from 24S-hydroxycholesterol and have 24S-,25R-
or 24S-,25S-stereochemistry [12].
A bile acid precursor prevalent in CSF is 7α,25-dihydroxy-3-ox-
ocholest-4-en-26-oic acid (Fig. 3). The identity of this metabolite was
conﬁrmed by comparison of retention time, exact mass and MS3 spectra
to that of the authentic standard 7α,25(R/S)-dihydroxy-3-oxocholest-4-
en-26-oic acid. The concentration of 7α,25-dihydroxy-3-oxocholest-4-
en-26-oic acid falls in CSF from 2.04 ± 0.61 ng/mL in the control
group to 1.63 ± 0.52 ng/mL in the AD group (Supplemental Fig. S5).
This diﬀerence is statistically signiﬁcant (P < 0.05). When measured
in ng/µg-cholesterol the control group and AD group concentrations are
2.97 ± 1.12 and 2.09 ± 0.8, respectively, in which case P < 0.01
(Fig. 4). Of all the bile acid precursors this was the only one found to be
changed signiﬁcantly in any of the patient-groups.
Fig. 3. (A) Multiple reaction monitoring (MRM) chromatograms corresponding to the transitions m/z 585.4→501.3→455.3 targeting [2H5]GP-derivatised dihy-
droxy-3-oxocholest-4-en-26-oic acids. The transition is particularly prominent in 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid (7α,25-diH,3O-CA) [12]. GP-de-
rivatives appear as twin peaks as a consequence of the formation of syn and anti conformers of the derivative. The upper panel displays a chromatogram from AD CSF,
the lower panel from control CSF. The measured concentrations (ng/mL) of 7α,25-diH,3O-CA are given in the right-hand corners of the chromatograms. (B) High-
resolution mass spectra of the syn and anti conformers of 7α,25-diH,3O-CA eluting at 2.94min (upper panel) and 3.85min (central panel) from the AD CSF sample
and the theoretical isotope pattern for their chemical formula C35H452H5O5N3+. MS3 spectra [M]+→[M-Py]+→ (m/z 585.4→501.3→), where Py is pyridine, from
the conformers eluting at (C) 2.94min (D) 3.82min from the AD sample and (E) the authentic standard of 7α,25(R/S)-dihydroxy-3-oxocholest-4-en-26-oic acid. The
high-resolution mass spectra shown in (B) were recorded in the Orbitrap analyser, other data was generated in the linear ion-trap of the Orbitrap Elite mass
spectrometer.
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3.3. Cholesterol
We also measured the levels of cholesterol and its precursors des-
mosterol and 7-dehydrocholesterol and the isomer 8-dehy-
drocholesterol. There was no statistical diﬀerence in concentrations of
these sterols between the diﬀerent sample groups (Fig. 5 and
Supplemental Fig. S6 and Table S4).
3.4. Pairwise correlation between CSF levels of analytes
Spearman's rank correlation can aid the determination of whether
the levels of two analytes correlate, either positively or negatively. The
higher or lower the statistical score for the correlation on a scale from
+100 to −100, the more likely it is that the analytes correlate posi-
tively or negatively. Scores are called the correlation coeﬃcients (r)
[40,41]. Shown in Fig. 6 is a heat map of Spearman's rank correlation
coeﬃcients (r) × 100 between the indicated pairs of analytes. A bipolar
gradient between red (positive correlation) and blue (negative corre-
lation) is indicated by the scale on the righthand side of the Figure.
Only values greater than± 40 show statistically signiﬁcant correlation
at a 1% signiﬁcance level. Values lower than± 40 have been marked
grey to show that these correlations are not statistically signiﬁcant.
Perhaps not surprisingly, 7α,25-dihydroxy-3-oxocholest-4-en-26-oic
acid positively correlates most strongly with other cholestenoic acids
Fig. 4. Dot-plots displaying the concentrations of diﬀerent dihydroxy-3-oxocholest-4-en-26-oic and chol-4-en-24-oic acids in CSF. Each dot indicates an individual
patient sample. Concentrations are in ng/µg-cholesterol. The black bar indicates the mean value. Only 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid showed a
statistical diﬀerence between disease and control groups. (A) 7αH,3O-Δ4-BA, 7α-hydroxy-3-oxochol-4-en-24-oic acid; (B) 7αH-26-nor-C-3,24-diO, 7α-hydroxy-26-
nor-cholest-4-en-3,24-dione; (C) 7α,24-diH,3O-CA, 7α,24-dihydroxy-3-oxocholest-4-en-26-oic acid; (D) 7α,x-diH,3O-CA, 7α,x-dihydroxy-3-oxocholest-4-en-26-oic
acid; (E) 7α,25-diH,3O-CA, 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid; (F) 7α,12α-diH,3O-CA, 7α,12α-dihydroxy-3-oxocholest-4-en-26-oic acid. 7α-Hydroxy-
26-nor-cholest-4-en-3,24-dione is formed by decarboxylation of 7α-hydroxy-3,24-bisoxocholest-4-en-26-oic acid [8]. The location of the second hydroxy group,
indicated by x, in 7α,x-diH,3O-CA is on the C17 side-chain, probably at C-22 or C-23 [12].
W.J. Griﬃths et al. Free Radical Biology and Medicine 134 (2019) 42–52
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Fig. 5. Dot-plots displaying the concentrations of a cholestatrien-3β-ol, desmosterol and 8-dehydrocholesterol in CSF. Each dot indicates an individual patient
sample. Concentrations are in ng/µg-cholesterol. The black bar indicates the mean value. (A) Triene, cholestatrien-3β-ol; (B) Des, desmosterol; (C) 8-DHC, 8-
dehydrocholesterol.
Fig. 6. Heat map generated using the program R version
3.2.2 displaying pairwise correlations between cholesterol
metabolite concentrations in human CSF samples. Values
in the heat map are Spearman's rank correlation coeﬃ-
cients (r) × 100 between the indicated pairs of metabo-
lites. A bipolar gradient between red (positive correlation)
and blue (negative correlation) is used. Only values
greater or lesser than± 40 show statistically signiﬁcant
correlation at a 1% signiﬁcance level. Values within± 40
have been marked grey to show that these correlations are
not statistically signiﬁcant. Abbreviations for cholesterol
metabolites are as in Figure Captions 1 – 5 and
Supplemental Table S2.
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and the C24 acid 7α-hydroxy-3-oxochol-4-en-24-oic acid. Interestingly,
it also correlates positively with 7α,(25 R)26-dihydroxycholest-4-en-3-
one, 7α,25-dihydroxycholest-4-en-3-one and (25 R)26-hydro-
xycholesterol.
4. Discussion
A limitation of the present study is a lack of isotope-labelled au-
thentic standards for many of the metabolites studied, necessitating the
use of structural analogues (See Supplemental Tables S2–S4). Earlier
studies by Crick et al. have indicated that this is a valid approach when
incorporating GP-derivatisation which equalises for structure-speciﬁc
variation in ionisation eﬃciency by incorporating a permanent posi-
tive-charge in the analyte [37]. Crick et al. have also shown that in the
absence of isotope-labelled standards correction for analyte loss during
sample preparation can made by the use of standards with similar hy-
drophobicity [37]. Here we have conﬁrmed this for 7α,25-dihydroxy-3-
oxocholest-4-en-26-oic acid by performing a standard additions ex-
periment, where R2 for the plot of measured concentration against
theoretical concentration was found to be> 0.994.
We have previously reported the presence of 7α,25-dihydroxy-3-
oxocholest-4-en-26-oic acid in human CSF [9,12], where, as here, the
identiﬁcation was made based on retention time, exact mass and MS3
spectra of the GP-derivative and comparison to the authentic standard
which was available as a mixture of 25R- and 25S-epimers. In the
present study, and those made earlier, we cannot be sure of the exact
stereochemistry at C-25 of the acid found in CSF. The origin of 7α,25-
dihydroxy-3-oxocholest-4-en-26-oic acid is possibly via CYP3A4 (cyto-
chrome P450 family 3 subfamily A member 4) catalysed 25-
hydroxylation after 7α-hydroxylation and before, or after, C-26-hy-
droxylation and -carboxylation by CYP27A1 (Fig. 7, see also
Supplemental Fig. S7) [12]. This would be consistent with 7α,25-di-
hydroxy-3-oxocholest-4-en-26-oic acid correlating positively with
7α,25-dihydroxycholest-4-en-3-one. We have demonstrated that
CYP3A4 hydroxylates 7α-hydroxycholesterol [42], while Honda et al.
have shown that CYP3A4, like CH25H (cholesterol 25-hydroxylase), is a
25-hydroxylase [43]. Alternatively, the start of the biosynthesis
pathway for 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid may be 25-
hydroxylation of cholesterol by CH25H [44].
The correlation data presented in Fig. 6 is consistent with 7α,25-
dihydroxy-3-oxocholest-4-en-26-oic acid being formed via the enzymes
CYP3A4, CYP27A1, HSD3B7 and either CYP7A1 or CYP7B1 (Fig. 7,
Supplemental Fig. S7). With the exception of CYP7A1, each of these
enzymes is known to be expressed in human brain [8,45–49], while 7α-
hydroxycholesterol is known to be present in rodent brain, presumably
originating in the periphery and crossing the BBB into brain or being
derived from non-enzymatic oxidation of cholesterol in brain [42].
CYP27A1 the enzyme required to introduce the carboxylic acid group at
C27 is expressed in neurons, oligodendrocytes and some astrocytes in
human brain, and in AD brain its expression is reduced in neurons but
increased in oligodendrocytes, perhaps reﬂecting a decrease and in-
crease in their respective cell numbers [46]. CYP3A4 is expressed in
neurons, primarily localized in the soma and axonal hillock [45] and
CYP7B1 is also expressed in neurons [49]. Yau et al. have shown that in
AD brain the per neuron levels of CYP7B1 mRNA are reduced in hip-
pocampul sections, suggesting a selective impairment in ability of AD
brain to 7α-hydroxylate oxysterols [49]. Conversely, HSD3B7 is not
expressed in neurons, only glia [48]. From the above we suggest that
Fig. 7. Potential routes of biosynthesis and metabolism of 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid in the CNS. Coloured bars indicate metabolites detected
but not changed in concentration, while coloured arrows indicate metabolites changed in concentration. Red, green and blue correspond to Alzheimer's disease,
vascular dementia or other neurodegenerative disease, respectively. Metabolites, named by red text show signiﬁcant Spearman's rank correlation coeﬃcients to
7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid. Abbreviations: CYP, cytochrome P450; HSD, hydroxysteroid dehydrogenase; AKR, aldo-keto reductase.
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the reduced level of 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid in
AD CSF is a consequence of a reduced synthesis, resulting from a loss of
neuron numbers. Of the cholestenoic acids monitored in this work, only
7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid was found to change in
abundance in any patient-group, this suggests that the enzyme re-
sponsible for 25-hydroxylation, either CH25H or CYP3A4, is critically
important for this eﬀect. CH25H is expressed in human cerebral cortex
and hippocamps inclusive of pyramidal neurons [48,50]. CH25H is
located on chromosome 10, close to the LIPA (lipase A, lysosomal acid
type) gene which codes for a lysosomal protein which hydrolyses
cholesterol esters, in a region strongly linked to AD [51]. Haplotypes in
the 5′ untranslated region of CH25H are associated with the risk of AD
[52,53]. Whatever the pathway of formation, we can only speculate
whether reduced synthesis of 7α,25-dihydroxy-3-oxocholest-4-en-26-
oic acid directly contributes to the pathophysiology of AD, as very little
is known of the biological activities of this molecule.
How 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid is metabolised
is not known. It may fall into the Duane bile acid biosynthesis pathway
[54] with formation of 7α,25-dihydroxy-3,24-bisoxocholest-4-en-26-oic
acid and elimination of 2-oxopropanoic acid with formation of 7α-hy-
droxy-3-oxochol-4-en-24-oic acid and ultimately chenodeoxycholic
acid or be reduced at Δ4 by AKR1D1 (aldo-keto reductase family 1
member D1) then at C-3 by AKR1C4 (aldo-keto reductase family 1
member C4) prior to C-24 carbonylation and elimination of 2-ox-
opropanoic acid (Fig. 7). Although AKR1D1 and 1C4 are usually re-
garded as liver speciﬁc, Mano et al. have shown that enzymes in the
cytosolic fraction prepared from rat brain can convert 7α-hydroxy-3-
oxochol-4-en-24-oic acid to chenodeoxycholic acid [55]. Whether these
enzymes are present in human brain and can similarly act on C27 acids
is unknown. Further studies of CSF targeting additional metabolites are
required to learn more about the metabolism of 7α,25-dihydroxy-3-
oxocholest-4-en-26-oic acid.
The authentic standard of 3β,7α,25-trihydroxycholest-5-en-26-oic
acid, from which 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid is
synthetically derived by bacterial cholesterol oxidase treatment, was
only recently custom synthesised by Avanti Polar Lipids Inc. We await
synthesis of an isotope-labelled version to fully validate the current
ﬁndings on a larger cohort of AD patients.
Previous studies have shown that the concentration of 7α,25-dihy-
droxy-3-oxocholest-4-en-26-oic acid in CSF is higher than in serum [9],
and we suggest that in the healthy brain 7α,25-dihydroxy-3-oxocholest-
4-en-26-oic acid provides a route for removal of cholesterol via meta-
bolism to more a hydrophilic metabolite. Its reduced concentration in
CSF of the AD patient-group suggests that this route is attenuated in this
disease state. It cannot be ruled out that, like many other cholesterol-
derived molecules, 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid may
also have signalling properties which become diminished in the disease
state. In light of the reduced level of 7α,25-dihydroxy-3-oxocholest-4-
en-26-oic acid in CSF of the AD patient-group it is tempting to devise
routes to enhance its formation. Although perhaps a naïve suggestion, if
CYP3A4 is the necessary 25-hydroxylase this could be up-regulated
through activation of the pregnane X receptor (PXR, NR1I2) or the
constitutive androstane receptor (CAR, NR1I3), as CYP3A4 is a target
gene of both PXR and CAR [56,57]. PXR is activated by multiple ago-
nists including dexamethasone, rifampicin and enzyme-inducing anti-
epileptics, as well as many constituents of herbal remedies, while CAR
is activated by several environmental chemicals and pharmaceuticals
[58–60]. In fact, the eﬀects in human of PXR activation by rifampicin,
also known as rifampin, which demonstrates good CNS penetration
[61], have recently been assessed in a randomized, open, placebo-
controlled crossover trial on an oral glucose tolerance test [62]. The
PXR agonists elicited postprandial hyperglycemia, suggesting a detri-
mental role of PXR activation on glucose tolerance. Although none of
the participants reached the clinical criterion of impaired glucose tol-
erance [62], there are obvious limitations of this approach. Alter-
natively, cholesterol 25-hydroxylase, CH25H, an interferon-stimulated
gene, may be activated via the interferon receptor [63]. Interestingly,
Merck KGaA have performed a clinical trial (ClinicalTrials.gov Identi-
ﬁer: NCT01075763) to evaluate interferon β-1a in the treatment of AD.
In summary, we have identiﬁed a statistically signiﬁcant reduction
of 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid in the CSF of the
patient-group with AD. Based on LC-MS identiﬁcation of cholesterol
metabolites and correlations of their concentrations, we suggest me-
chanisms for the formation of 7α,25-dihydroxy-3-oxocholest-4-en-26-
oic acid. Interestingly, one of the suggested pathways relies on CH25H,
an interferon stimulated gene implicated in AD.
Acknowledgements
This work was supported by the UK Biotechnology and Biological
Sciences Research Council (BBSRC, grant numbers BB/I001735/1 and
BB/N015932/1 to WJG, BB/L001942/1 to YW), an Engineering and
Physical Sciences Research Council Impact Acceleration Account (to
Swansea University), the Welsh Government (A4B grant to WJG and
YW), the Swedish Science Council (grant to JÅG) and the Robert A.
Welch Fund (Grant E-0004 to JÅG). JAK was supported by a Ph.D.
studentship from Imperial College Healthcare Charities. Members of the
European Network for Oxysterol Research (ENOR, https://www.
oxysterols.net/) are thanked for informative discussions.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at doi:10.1016/j.freeradbiomed.2018.12.020.
References
[1] E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell,
G.W. Small, A.D. Roses, J.L. Haines, M.A. Pericak-Vance, Gene dose of apolipo-
protein E type 4 allele and the risk of Alzheimer's disease in late onset families,
Science 261 (1993) 921–923.
[2] W.J. Strittmatter, K.H. Weisgraber, D.Y. Huang, L.M. Dong, G.S. Salvesen,
M. Pericak-Vance, D. Schmechel, A.M. Saunders, D. Goldgaber, A.D. Roses, Binding
of human apolipoprotein E to synthetic amyloid beta peptide: isoform-speciﬁc ef-
fects and implications for late-onset Alzheimer disease, Proc. Natl. Acad. Sci. USA
90 (1993) 8098–8102.
[3] J.C. Lambert, C.A. Ibrahim-Verbaas, D. Harold, A.C. Naj, R. Sims, C. Bellenguez,
A.L. DeStafano, J.C. Bis, G.W. Beecham, B. Grenier-Boley, G. Russo, T.A. Thorton-
Wells, N. Jones, A.V. Smith, V. Chouraki, C. Thomas, M.A. Ikram, D. Zelenika,
B.N. Vardarajan, Y. Kamatani, C.F. Lin, A. Gerrish, H. Schmidt, B. Kunkle,
M.L. Dunstan, A. Ruiz, M.T. Bihoreau, S.H. Choi, C. Reitz, F. Pasquier, C. Cruchaga,
D. Craig, N. Amin, C. Berr, O.L. Lopez, P.L. De Jager, V. Deramecourt,
J.A. Johnston, D. Evans, S. Lovestone, L. Letenneur, F.J. Moron, D.C. Rubinsztein,
G. Eiriksdottir, K. Sleegers, A.M. Goate, N. Fievet, M.W. Huentelman, M. Gill,
K. Brown, M.I. Kamboh, L. Keller, P. Barberger-Gateau, B. McGuiness, E.B. Larson,
R. Green, A.J. Myers, C. Dufouil, S. Todd, D. Wallon, S. Love, E. Rogaeva,
J. Gallacher, P. St George-Hyslop, J. Clarimon, A. Lleo, A. Bayer, D.W. Tsuang,
L. Yu, M. Tsolaki, P. Bossu, G. Spalletta, P. Proitsi, J. Collinge, S. Sorbi, F. Sanchez-
Garcia, N.C. Fox, J. Hardy, M.C. Deniz Naranjo, P. Bosco, R. Clarke, C. Brayne,
D. Galimberti, M. Mancuso, F. Matthews, European Alzheimer's Disease Initiative,
Genetic and Environmental Risk in Alzheimer's Disease, Alzheimer's Disease
Genetic Consortium, Cohorts for Heart and Aging Research in Genomic
Epidemiology, S. Moebus, P. Mecocci, M. Del Zompo, W. Maier, H. Hampel,
A. Pilotto, M. Bullido, F. Panza, P. Caﬀarra, B. Nacmias, J.R. Gilbert, M. Mayhaus,
L. Lannefelt, H. Hakonarson, S. Pichler, M.M. Carrasquillo, M. Ingelsson, D. Beekly,
V. Alvarez, F. Zou, O. Valladares, S.G. Younkin, E. Coto, K.L. Hamilton-Nelson,
W. Gu, C. Razquin, P. Pastor, I. Mateo, M.J. Owen, K.M. Faber, P.V. Jonsson,
O. Combarros, M.C. O'Donovan, L.B. Cantwell, H. Soininen, D. Blacker, S. Mead,
T.H. Mosley Jr., D.A. Bennett, T.B. Harris, L. Fratiglioni, C. Holmes, R.F. de Bruijn,
P. Passmore, T.J. Montine, K. Bettens, J.I. Rotter, A. Brice, K. Morgan, T.M. Foroud,
W.A. Kukull, D. Hannequin, J.F. Powell, M.A. Nalls, K. Ritchie, K.L. Lunetta,
J.S. Kauwe, E. Boerwinkle, M. Riemenschneider, M. Boada, M. Hiltuenen,
E.R. Martin, R. Schmidt, D. Rujescu, L.S. Wang, J.F. Dartigues, R. Mayeux,
C. Tzourio, A. Hofman, M.M. Nothen, C. Graﬀ, B.M. Psaty, L. Jones, J.L. Haines,
P.A. Holmans, M. Lathrop, M.A. Pericak-Vance, L.J. Launer, L.A. Farrer, C.M. van
Duijn, C. Van Broeckhoven, V. Moskvina, S. Seshadri, J. Williams,
G.D. Schellenberg, P. Amouyel, Meta-analysis of 74,046 individuals identiﬁes 11
new susceptibility loci for Alzheimer's disease, Nat Genet, (2013), pp. 1452–1458.
[4] G.W. Beecham, K. Hamilton, A.C. Naj, E.R. Martin, M. Huentelman, A.J. Myers,
J.J. Corneveaux, J. Hardy, J.P. Vonsattel, S.G. Younkin, D.A. Bennett, P.L. De Jager,
E.B. Larson, P.K. Crane, M.I. Kamboh, J.K. Koﬂer, D.C. Mash, L. Duque, J.R. Gilbert,
H. Gwirtsman, J.D. Buxbaum, P. Kramer, D.W. Dickson, L.A. Farrer, M.P. Frosch,
W.J. Griﬃths et al. Free Radical Biology and Medicine 134 (2019) 42–52
50
B. Ghetti, J.L. Haines, B.T. Hyman, W.A. Kukull, R.P. Mayeux, M.A. Pericak-Vance,
J.A. Schneider, J.Q. Trojanowski, E.M. Reiman, C. Alzheimer's Disease Genetics,
G.D. Schellenberg, T.J. Montine, Genome-wide association meta-analysis of neu-
ropathologic features of Alzheimer's disease and related dementias, PLoS Genet. 10
(2014) e1004606.
[5] C. Picard, C. Julien, J. Frappier, J. Miron, L. Theroux, D. Dea, C. United Kingdom
Brain Expression, I. for the Alzheimer's Disease Neuroimaging, J.C.S. Breitner,
J. Poirier, Alterations in cholesterol metabolism-related genes in sporadic
Alzheimer's disease, Neurobiol. Aging 66 (2018) 180e181–180e189.
[6] J.M. Dietschy, S.D. Turley, Thematic review series: brain lipids. cholesterol meta-
bolism in the central nervous system during early development and in the mature
animal, J. Lipid Res. 45 (2004) 1375–1397.
[7] W.J. Griﬃths, J. Abdel-Khalik, E. Yutuc, A.H. Morgan, I. Gilmore, T. Hearn,
Y. Wang, Cholesterolomics: an update, Anal. Biochem. 524 (2017) 56–67.
[8] M. Ogundare, S. Theoﬁlopoulos, A. Lockhart, L.J. Hall, E. Arenas, J. Sjovall,
A.G. Brenton, Y. Wang, W.J. Griﬃths, Cerebrospinal ﬂuid steroidomics: are
bioactive bile acids present in brain? J. Biol. Chem. 285 (2010) 4666–4679.
[9] J. Abdel-Khalik, E. Yutuc, P.J. Crick, J.A. Gustafsson, M. Warner, G. Roman,
K. Talbot, E. Gray, W.J. Griﬃths, M.R. Turner, Y. Wang, Defective cholesterol
metabolism in amyotrophic lateral sclerosis, J. Lipid Res. 58 (2017) 267–278.
[10] L.L. Smith, D.R. Ray, J.A. Moody, J.D. Wells, J.E. Van Lier, 24-hydroxycholesterol
levels in human brain, J. Neurochem. 19 (1972) 899–904.
[11] E.G. Lund, J.M. Guileyardo, D.W. Russell, cDNA cloning of cholesterol 24-hydro-
xylase, a mediator of cholesterol homeostasis in the brain, Proc. Natl. Acad. Sci.
USA 96 (1999) 7238–7243.
[12] J. Abdel-Khalik, P.J. Crick, E. Yutuc, A.E. DeBarber, P.B. Duell, R.D. Steiner,
I. Laina, Y. Wang, W.J. Griﬃths, Identiﬁcation of 7alpha,24-dihydroxy-3-ox-
ocholest-4-en-26-oic and 7alpha,25-dihydroxy-3-oxocholest-4-en-26-oic acids in
human cerebrospinal ﬂuid and plasma, Biochimie 153 (2018) 86–98.
[13] D. Lutjohann, O. Breuer, G. Ahlborg, I. Nennesmo, A. Siden, U. Diczfalusy,
I. Bjorkhem, Cholesterol homeostasis in human brain: evidence for an age-depen-
dent ﬂux of 24S-hydroxycholesterol from the brain into the circulation, Proc. Natl.
Acad. Sci. USA 93 (1996) 9799–9804.
[14] I. Bjorkhem, M. Heverin, V. Leoni, S. Meaney, U. Diczfalusy, Oxysterols and
Alzheimer's disease, Acta Neurol. Scand. Suppl. 185 (2006) 43–49.
[15] M. Heverin, S. Meaney, D. Lutjohann, U. Diczfalusy, J. Wahren, I. Bjorkhem,
Crossing the barrier: net ﬂux of 27-hydroxycholesterol into the human brain, J.
Lipid Res. 46 (2005) 1047–1052.
[16] L. Iuliano, P.J. Crick, C. Zerbinati, L. Tritapepe, J. Abdel-Khalik, M. Poirot, Y. Wang,
W.J. Griﬃths, Cholesterol metabolites exported from human brain, Steroids 99
(2015) 189–193.
[17] M. Heverin, N. Bogdanovic, D. Lutjohann, T. Bayer, I. Pikuleva, L. Bretillon,
U. Diczfalusy, B. Winblad, I. Bjorkhem, Changes in the levels of cerebral and ex-
tracerebral sterols in the brain of patients with Alzheimer's disease, J. Lipid Res. 45
(2004) 186–193.
[18] A. Papassotiropoulos, D. Lutjohann, M. Bagli, S. Locatelli, F. Jessen, R. Buschfort,
U. Ptok, I. Bjorkhem, K. von Bergmann, R. Heun, 24S-hydroxycholesterol in cere-
brospinal ﬂuid is elevated in early stages of dementia, J. Psychiatr. Res. 36 (2002)
27–32.
[19] P. Schonknecht, D. Lutjohann, J. Pantel, H. Bardenheuer, T. Hartmann, K. von
Bergmann, K. Beyreuther, J. Schroder, Cerebrospinal ﬂuid 24S-hydroxycholesterol
is increased in patients with Alzheimer's disease compared to healthy controls,
Neurosci. Lett. 324 (2002) 83–85.
[20] N. Bogdanovic, L. Bretillon, E.G. Lund, U. Diczfalusy, L. Lannfelt, B. Winblad,
D.W. Russell, I. Bjorkhem, On the turnover of brain cholesterol in patients with
Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46
in glial cells, Neurosci. Lett. 314 (2001) 45–48.
[21] Y. Wang, S. Muneton, J. Sjovall, J.N. Jovanovic, W.J. Griﬃths, The eﬀect of 24S-
hydroxycholesterol on cholesterol homeostasis in neurons: quantitative changes to
the cortical neuron proteome, J. Proteome Res. 7 (2008) 1606–1614.
[22] K. Abildayeva, P.J. Jansen, V. Hirsch-Reinshagen, V.W. Bloks, A.H. Bakker,
F.C. Ramaekers, J. de Vente, A.K. Groen, C.L. Wellington, F. Kuipers, M. Mulder,
24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in
astrocytes that regulates apolipoprotein E-mediated cholesterol eﬄux, J. Biol.
Chem. 281 (2006) 12799–12808.
[23] M. Warner, J.A. Gustafsson, Estrogen receptor beta and Liver X receptor beta:
biology and therapeutic potential in CNS diseases, Mol. Psychiatry 20 (2015)
18–22.
[24] J.M. Lehmann, S.A. Kliewer, L.B. Moore, T.A. Smith-Oliver, B.B. Oliver, J.L. Su,
S.S. Sundseth, D.A. Winegar, D.E. Blanchard, T.A. Spencer, T.M. Willson, Activation
of the nuclear receptor LXR by oxysterols deﬁnes a new hormone response pathway,
J. Biol. Chem. 272 (1997) 3137–3140.
[25] V. Leoni, M. Shafaati, A. Salomon, M. Kivipelto, I. Bjorkhem, L.O. Wahlund, Are the
CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive im-
pairment? Neurosci. Lett. 397 (2006) 83–87.
[26] L. Mateos, M.A. Ismail, F.J. Gil-Bea, V. Leoni, B. Winblad, I. Bjorkhem, A. Cedazo-
Minguez, Upregulation of brain renin angiotensin system by 27-hydroxycholesterol
in Alzheimer's disease, J. Alzheimers Dis. 24 (2011) 669–679.
[27] P.J. Crick, L. Beckers, M. Baes, P.P. Van Veldhoven, Y. Wang, W.J. Griﬃths, The
oxysterol and cholestenoic acid proﬁle of mouse cerebrospinal ﬂuid, Steroids 99
(2015) 172–177.
[28] S. Theoﬁlopoulos, W.J. Griﬃths, P.J. Crick, S. Yang, A. Meljon, M. Ogundare,
S.S. Kitambi, A. Lockhart, K. Tuschl, P.T. Clayton, A.A. Morris, A. Martinez,
M.A. Reddy, A. Martinuzzi, M.T. Bassi, A. Honda, T. Mizuochi, A. Kimura,
H. Nittono, G. De Michele, R. Carbone, C. Criscuolo, J.L. Yau, J.R. Seckl, R. Schule,
L. Schols, A.W. Sailer, J. Kuhle, M.J. Fraidakis, J.A. Gustafsson, K.R. Steﬀensen,
I. Bjorkhem, P. Ernfors, J. Sjovall, E. Arenas, Y. Wang, Cholestenoic acids regulate
motor neuron survival via liver X receptors, J. Clin. Investig. 124 (2014)
4829–4842.
[29] S. Theoﬁlopoulos, Y. Wang, S.S. Kitambi, P. Sacchetti, K.M. Sousa, K. Bodin, J. Kirk,
C. Salto, M. Gustafsson, E.M. Toledo, K. Karu, J.A. Gustafsson, K.R. Steﬀensen,
P. Ernfors, J. Sjovall, W.J. Griﬃths, E. Arenas, Brain endogenous liver X receptor
ligands selectively promote midbrain neurogenesis, Nat. Chem. Biol. 9 (2013)
126–133.
[30] S. Ferdinandusse, S. Denis, P.L. Faust, R.J. Wanders, Bile acids: the role of peroxi-
somes, J. Lipid Res. 50 (2009) 2139–2147.
[31] N. Mano, T. Goto, M. Uchida, K. Nishimura, M. Ando, N. Kobayashi, J. Goto,
Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat
brain, J. Lipid Res. 45 (2004) 295–300.
[32] T. Higashi, S. Watanabe, K. Tomaru, W. Yamazaki, K. Yoshizawa, S. Ogawa,
H. Nagao, K. Minato, M. Maekawa, N. Mano, Unconjugated bile acids in rat brain:
analytical method based on LC/ESI-MS/MS with chemical derivatization and esti-
mation of their origin by comparison to serum levels, Steroids 125 (2017) 107–113.
[33] X. Pan, C.T. Elliott, B. McGuinness, P. Passmore, P.G. Kehoe, C. Holscher,
P.L. McClean, S.F. Graham, B.D. Green, Metabolomic proﬁling of bile acids in
clinical and experimental samples of Alzheimer's Disease, Metabolites 7 (2017).
[34] J. Marksteiner, I. Blasko, G. Kemmler, T. Koal, C. Humpel, Bile acid quantiﬁcation
of 20 plasma metabolites identiﬁes lithocholic acid as a putative biomarker in
Alzheimer's disease, Metabolomics 14 (2018) 1.
[35] N. Greenberg, A. Grassano, M. Thambisetty, S. Lovestone, C. Legido-Quigley, A
proposed metabolic strategy for monitoring disease progression in Alzheimer's
disease, Electrophoresis 30 (2009) 1235–1239.
[36] P.J. Crick, T.W. Bentley, Y. Wang, W.J. Griﬃths, Revised sample preparation for the
analysis of oxysterols by enzyme-assisted derivatisation for sterol analysis (EADSA),
Anal. Bioanal. Chem. 407 (2015) 5235–5239.
[37] P.J. Crick, T. William Bentley, J. Abdel-Khalik, I. Matthews, P.T. Clayton,
A.A. Morris, B.W. Bigger, C. Zerbinati, L. Tritapepe, L. Iuliano, Y. Wang,
W.J. Griﬃths, Quantitative charge-tags for sterol and oxysterol analysis, Clin.
Chem. 61 (2015) 400–411.
[38] K. Karu, M. Hornshaw, G. Woﬀendin, K. Bodin, M. Hamberg, G. Alvelius, J. Sjovall,
J. Turton, Y. Wang, W.J. Griﬃths, Liquid chromatography-mass spectrometry uti-
lizing multi-stage fragmentation for the identiﬁcation of oxysterols, J. Lipid Res. 48
(2007) 976–987.
[39] S. Ferdinandusse, S. Denis, H. Overmars, L. Van Eeckhoudt, P.P. Van Veldhoven,
M. Duran, R.J. Wanders, M. Baes, Developmental changes of bile acid composition
and conjugation in L- and D-bifunctional protein single and double knockout mice,
J. Biol. Chem. 280 (2005) 18658–18666.
[40] A.R. Stiles, J. Kozlitina, B.M. Thompson, J.G. McDonald, K.S. King, D.W. Russell,
Genetic, anatomic, and clinical determinants of human serum sterol and vitamin D
levels, Proc. Natl. Acad. Sci. USA 111 (2014) E4006–E4014.
[41] M.M. Mukaka, Statistics corner: a guide to appropriate use of correlation coeﬃcient
in medical research, Malawi Med. J. 24 (2012) 69–71.
[42] W.J. Griﬃths, P.J. Crick, A. Meljon, S. Theoﬁlopoulos, J. Abdel-Khalik, E. Yutuc,
J.E. Parker, D.E. Kelly, S.L. Kelly, E. Arenas, Y. Wang, Additional pathways of Sterol
metabolism: evidence from analysis of Cyp27a1-/- mouse brain and plasma, BBA -
Mol. Cell Biol. Lipids (2018).
[43] A. Honda, T. Miyazaki, T. Ikegami, J. Iwamoto, T. Maeda, T. Hirayama, Y. Saito,
T. Teramoto, Y. Matsuzaki, Cholesterol 25-hydroxylation activity of CYP3A, J. Lipid
Res. 52 (2011) 1509–1516.
[44] E.G. Lund, T.A. Kerr, J. Sakai, W.P. Li, D.W. Russell, cDNA cloning of mouse and
human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a
potent oxysterol regulator of lipid metabolism, J. Biol. Chem. 273 (1998)
34316–34327.
[45] I.M. Booth Depaz, F. Toselli, P.A. Wilce, E.M. Gillam, Diﬀerential expression of
human cytochrome P450 enzymes from the CYP3A subfamily in the brains of al-
coholic subjects and drug-free controls, Drug Metab. Dispos. 41 (2013) 1187–1194.
[46] J. Brown 3rd, C. Theisler, S. Silberman, D. Magnuson, N. Gottardi-Littell, J.M. Lee,
D. Yager, J. Crowley, K. Sambamurti, M.M. Rahman, A.B. Reiss, C.B. Eckman,
B. Wolozin, Diﬀerential expression of cholesterol hydroxylases in Alzheimer's dis-
ease, J. Biol. Chem. 279 (2004) 34674–34681.
[47] W.L. Liao, G.Y. Heo, N.G. Dodder, R.E. Reem, N. Mast, S. Huang, P.L. Dipatre,
I.V. Turko, I.A. Pikuleva, Quantiﬁcation of cholesterol-metabolizing P450s
CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product corre-
lations in human retina but not human brain, J. Proteome Res. 10 (2011) 241–248.
[48] M. Uhlen, L. Fagerberg, B.M. Hallstrom, C. Lindskog, P. Oksvold, A. Mardinoglu,
A. Sivertsson, C. Kampf, E. Sjostedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg,
S. Navani, C.A. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober,
T. Alm, P.H. Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson,
J.M. Schwenk, M. Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson,
M. Zwahlen, G. von Heijne, J. Nielsen, F. Ponten, Proteomics. tissue-based map of
the human proteome, Science 347 (2015) 1260419.
[49] J.L. Yau, S. Rasmuson, R. Andrew, M. Graham, J. Noble, T. Olsson, E. Fuchs,
R. Lathe, J.R. Seckl, Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant
expression in primate hippocampus and reduced expression in Alzheimer's disease,
Neuroscience 121 (2003) 307–314.
[50] I.S. Piras, J. Krate, I. Schrauwen, J.J. Corneveaux, G.E. Serrano, L. Sue, T.G. Beach,
M.J. Huentelman, Whole transcriptome proﬁling of the human hippocampus sug-
gests an involvement of the KIBRA rs17070145 polymorphism in diﬀerential acti-
vation of the MAPK signaling pathway, Hippocampus 27 (2017) 784–793.
[51] A. Myers, F. Wavrant De-Vrieze, P. Holmans, M. Hamshere, R. Crook, D. Compton,
H. Marshall, D. Meyer, S. Shears, J. Booth, D. Ramic, H. Knowles, J.C. Morris,
N. Williams, N. Norton, R. Abraham, P. Kehoe, H. Williams, V. Rudrasingham,
W.J. Griﬃths et al. Free Radical Biology and Medicine 134 (2019) 42–52
51
F. Rice, P. Giles, N. Tunstall, L. Jones, S. Lovestone, J. Williams, M.J. Owen,
J. Hardy, A. Goate, Full genome screen for Alzheimer disease: stage II analysis, Am.
J. Med. Genet. 114 (2002) 235–244.
[52] M.A. Wollmer, Cholesterol-related genes in Alzheimer's disease, Biochim. Biophys.
Acta 2010 (1801) 762–773.
[53] A. Papassotiropoulos, J.C. Lambert, F. Wavrant-De Vrieze, M.A. Wollmer, H. von
der Kammer, J.R. Streﬀer, A. Maddalena, K.D. Huynh, S. Wolleb, D. Lutjohann,
B. Schneider, D.R. Thal, L.M. Grimaldi, M. Tsolaki, E. Kapaki, R. Ravid,
U. Konietzko, T. Hegi, T. Pasch, H. Jung, H. Braak, P. Amouyel, E.I. Rogaev,
J. Hardy, C. Hock, R.M. Nitsch, Cholesterol 25-hydroxylase on chromosome 10q is a
susceptibility gene for sporadic Alzheimer's disease, Neurodegener. Dis. 2 (2005)
233–241.
[54] W.C. Duane, P.A. Pooler, J.N. Hamilton, Bile acid synthesis in man. In vivo activity
of the 25-hydroxylation pathway, J. Clin. Investig. 82 (1988) 82–85.
[55] N. Mano, Y. Sato, M. Nagata, T. Goto, J. Goto, Bioconversion of 3beta-hydroxy-5-
cholenoic acid into chenodeoxycholic acid by rat brain enzyme systems, J. Lipid
Res. 45 (2004) 1741–1748.
[56] S.A. Kliewer, J.T. Moore, L. Wade, J.L. Staudinger, M.A. Watson, S.A. Jones,
D.D. McKee, B.B. Oliver, T.M. Willson, R.H. Zetterstrom, T. Perlmann,
J.M. Lehmann, An orphan nuclear receptor activated by pregnanes deﬁnes a novel
steroid signaling pathway, Cell 92 (1998) 73–82.
[57] U.M. Zanger, M. Schwab, Cytochrome P450 enzymes in drug metabolism: regula-
tion of gene expression, enzyme activities, and impact of genetic variation,
Pharmacol. Ther. 138 (2013) 103–141.
[58] J.M. Lehmann, D.D. McKee, M.A. Watson, T.M. Willson, J.T. Moore, S.A. Kliewer,
The human orphan nuclear receptor PXR is activated by compounds that regulate
CYP3A4 gene expression and cause drug interactions, J. Clin. Investig. 102 (1998)
1016–1023.
[59] J. Hukkanen, Induction of cytochrome P450 enzymes: a view on human in vivo
ﬁndings, Expert Rev. Clin. Pharmacol. 5 (2012) 569–585.
[60] X.C. Kretschmer, W.S. Baldwin, CAR and PXR: xenosensors of endocrine disrupters?
Chem. Biol. Interact. 155 (2005) 111–128.
[61] A.K. Sullins, S.M. Abdel-Rahman, Pharmacokinetics of antibacterial agents in the
CSF of children and adolescents, Paediatr. Drugs 15 (2013) 93–117.
[62] J. Rysa, M. Buler, M.J. Savolainen, H. Ruskoaho, J. Hakkola, J. Hukkanen, Pregnane
X receptor agonists impair postprandial glucose tolerance, Clin. Pharmacol. Ther.
93 (2013) 556–563.
[63] J.G. McDonald, D.W. Russell, Editorial: 25-hydroxycholesterol: a new life in im-
munology, J. Leukoc. Biol. 88 (2010) 1071–1072.
W.J. Griﬃths et al. Free Radical Biology and Medicine 134 (2019) 42–52
52
